DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

High Dose BAYA1040_Nifedipine: a Long Term Combination Study

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Nifedipine (Adalat, BAYA1040) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer


This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at target blood pressure by the combination of BAYA1040_Nifedipine 40 mg once daily and other antihypertensives.

Clinical Details

Official title: A Multicenter, Open Label, Long Term Study of Oral BAYA1040_CR 80 mg (40 mg Bid) in Combination With Other Antihypertensives for 52 Weeks in Patients With Essential Hypertension

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Efficacy changes measured by sitting diastolic blood pressure (DBP)

Secondary outcome:

Efficacy changes measured by sitting systolic blood pressure (SBP)

Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines

Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP

Safety variables


Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- 20 years or older

- Japanese male or female

- Outpatient with essential hypertension

- Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive

drug (other than Ca antagonists) for 4 weeks or more before entry in this study Exclusion Criteria:

- Patients whose sitting diastolic blood pressure (DBP) is 110 mm Hg or more

- Patients with secondary hypertension or hypertensive emergency

Locations and Contacts

Ebina, Kanagawa 243-0401, Japan

Sagamihara, Kanagawa 252-0311, Japan

Kawaguchi, Saitama 332-0012, Japan

Shinjuku, Tokyo 169-0072, Japan

Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Click here to find results for studies related to Bayer Healthcare products.

Starting date: February 2011
Last updated: June 20, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017